Amgen (AMGN) : Trimtabs Asset Management reduced its stake in Amgen by 10.42% during the most recent quarter end. The investment management company now holds a total of 10,362 shares of Amgen which is valued at $1,797,082 after selling 1,205 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Amgen makes up approximately 1.12% of Trimtabs Asset Management’s portfolio.
Other Hedge Funds, Including , New Amsterdam Partnersny added AMGN to its portfolio by purchasing 2,683 company shares during the most recent quarter which is valued at $465,313. Amgen makes up approx 0.11% of New Amsterdam Partnersny’s portfolio.First National Bank Sioux Falls boosted its stake in AMGN in the latest quarter, The investment management firm added 68 additional shares and now holds a total of 168 shares of Amgen which is valued at $28,674. Amgen makes up approx 0.09% of First National Bank Sioux Falls’s portfolio.Ibm Retirement Fund reduced its stake in AMGN by selling 309 shares or 0.31% in the most recent quarter. The Hedge Fund company now holds 98,741 shares of AMGN which is valued at $16,358,421. Amgen makes up approx 0.58% of Ibm Retirement Fund’s portfolio.Jlb Associates Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 697 additional shares and now holds a total of 49,071 shares of Amgen which is valued at $8,129,593. Amgen makes up approx 2.24% of Jlb Associates Inc’s portfolio.Gateway Investment Advisers reduced its stake in AMGN by selling 6,545 shares or 1.25% in the most recent quarter. The Hedge Fund company now holds 517,128 shares of AMGN which is valued at $83,009,387. Amgen makes up approx 0.70% of Gateway Investment Advisers’s portfolio.
Amgen closed down -0.76 points or -0.44% at $172.67 with 21,22,162 shares getting traded on Thursday. Post opening the session at $173.3, the shares hit an intraday low of $172.04 and an intraday high of $173.67 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.